GMAB — Genmab A/S
$43.79+9.47%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for GMAB in the TickerWise workspace.
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: DK
- Exchange: NASDAQ
- Employees: 2,638
- Website: https://www.genmab.com
Latest SEC filings for GMAB
Latest GMAB news
- Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer Read article
- Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer Read article
- Genmab rises, Corcept falls on late-stage antibody-conjugate data for ovarian cancer Read article
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026 Read article
- Genmab: Epkinly Shines In Phase 3 DLBCL Trial Read article
- Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? Read article
- Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug Read article
- Genmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatment Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.